SEARCH:   Advanced

Blood, Vol. 109, Issue 8, 3400-3408, April 15, 2007 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia Blood Shankar et al. 109: 3400 Supplemental materials for: Shankar et al, Vol 109, Issue 8, 3400-3408 Files in this Data Supplement: Table S1. Percentage of blasts in the bone marrow from patients with AML at diagnosis (PDF, 11 KB) - Summary of the number of blasts and FLT3-ITD status in primary AML samples tested with the inhibitor. Figure S1. Hierarchial cluster heatmap of Ki values (nM) for various FLT3 and VEGFR/PDGFR inhibitors (PDF, 37.9 KB) - IC50 values were determined by homogenous time-resolved fluorescence (HTRF) at 1 mM ATP; these values were mathematically transformed into Ki values based on the experimentally determined Km (ATP) for each enzyme in the 79-kinase panel. Hierarchical cluster analysis was performed using Spotfire software (Spotfire, Sommerville, MA). Figure S2. Dose response of ABT-869 in wt-FLT3 AML patient samples (PDF, 29.7 KB) - Colonies were distinguished as CFU-E and CFU-GM in these samples. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020